FSP-FINNISH-STEEL
23.4.2021 11:03:07 CEST | Business Wire | Press release
Hiab, part of Cargotec, and FSP Finnish Steel Painting Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland as of April 2021. Following the partnership FSP will provide Hiab Poland the surface treatment services and the expertise in development techniques.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005017/en/
The surface treatment operation in Hiab’s Stargard multi-assembly unit and its associated professionals will transfer to FSP under their current employment conditions. The purpose of the agreement is to intensify the cooperation between Hiab and FSP so that the parties can focus on their own core competencies and improve business development.
For several years, FSP has been responsible for the surface treatment of Hiab’s MULTILIFT products in Finland. We have had an intense collaboration and established joint investments with Hiab. FSP is seeking international growth. ‘Thus, intensifying the collaboration further with Hiab was an anticipated consequence’, said FSP’s Chief Executive Officer Jarno Huttunen.
The new partnership will ensure Hiab continues with the latest in desired processes and technology. The facilities are equipped with a modern, cutting edge anti-corrosion treatment production line with an option for e-coating. The number of our personnel in Poland now consists of over a hundred professionals. These factors will provide us with more prospects in the future and enhance our resilience. This of course upgrades FSP’s service level in Poland, Huttunen continued. The multi-assembly unit is in the city of Stargard, in Poland.
The extension of the cooperation between the two giants creates a competitive advantage in surface treatment quality and technological leadership.
Hiab is a part of Cargotec Corporation. Cargotec enables smarter cargo flow for a better everyday with its leading cargo handling solutions and services. Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions.
FSP has been Hiab’s business associate for several years. FSP's role as Hiab's surface treatment expert partner is to create added value. We believe that FSP continues to respond to our demands in both delivery accuracy and quality, said Hiab’s Barry McGrane - Senior Vice President of LM Loader Cranes
Together we will continue to increase our competitive advantage in the fields of quality and technological leadership. The objective is to improve the efficiency, innovation, reliability of the surface treatment operations in the short and long term and we look forward to strengthening the partnership between both businesses,” Barry McGrane continues.
Cargotec Hiab
Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions. Hiab's class-leading load handling equipment includes HIAB, EFFER and ARGOS loader cranes, LOGLIFT and JONSERED forestry and recycling cranes, MOFFETT and PRINCETON truck mounted forklifts, MULTILIFT skip loaders and hooklifts, and tail lifts under the ZEPRO, DEL, and WALTCO brands. As the industry pioneer and with a proud 75 year history, Hiab is committed to be the preferred partner and solution provider to its customers and shape the future of intelligent load handling. www.hiab.com Hiab is part of Cargotec Corporation. www.cargotec.com
FSP Finnish Steel Painting Oy
FSP Finnish Steel Painting Oy is one of Europe's leading surface treatment companies. We employ more than 300 professionals and have a turnover of approximately EUR 26 million.
We offer industrial surface treatment and related design and value-added services. Our service covers the surface treatment process throughout the product's life cycle, from the definition of operating conditions to surface treatment, inspections and post-warranty maintenance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom